152 related articles for article (PubMed ID: 34607678)
21. Phase 1b study to investigate the safety and tolerability of idelalisib in Japanese patients with relapsed/refractory follicular lymphoma and chronic lymphocytic leukemia.
Fukuhara N; Kinoshita T; Yamamoto K; Nagai H; Izutsu K; Yamamoto G; Bhargava P; Rajakumaraswamy N; Humeniuk R; Mathias A; Xing G; Fukui M; Tobinai K
Jpn J Clin Oncol; 2020 Dec; 50(12):1395-1402. PubMed ID: 32856068
[TBL] [Abstract][Full Text] [Related]
22. FDA approval: idelalisib monotherapy for the treatment of patients with follicular lymphoma and small lymphocytic lymphoma.
Miller BW; Przepiorka D; de Claro RA; Lee K; Nie L; Simpson N; Gudi R; Saber H; Shord S; Bullock J; Marathe D; Mehrotra N; Hsieh LS; Ghosh D; Brown J; Kane RC; Justice R; Kaminskas E; Farrell AT; Pazdur R
Clin Cancer Res; 2015 Apr; 21(7):1525-9. PubMed ID: 25645861
[TBL] [Abstract][Full Text] [Related]
23. Transient hypophysitis in a patient treated by duvelisib for chronic lymphocytic leukemia.
Orioli L; Sarti K; Van Den Neste E; Maiter D
Ann Hematol; 2017 Apr; 96(4):685-686. PubMed ID: 28150013
[No Abstract] [Full Text] [Related]
24. Duvelisib in haematological malignancies.
Das M
Lancet Oncol; 2018 Nov; 19(11):e586. PubMed ID: 30318318
[No Abstract] [Full Text] [Related]
25. The PI3K pathway: clinical inhibition in chronic lymphocytic leukemia.
Brown JR
Semin Oncol; 2016 Apr; 43(2):260-4. PubMed ID: 27040704
[TBL] [Abstract][Full Text] [Related]
26. Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma.
Keating GM
Drugs; 2010 Jul; 70(11):1445-76. PubMed ID: 20614951
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells.
Göckeritz E; Kerwien S; Baumann M; Wigger M; Vondey V; Neumann L; Landwehr T; Wendtner CM; Klein C; Liu N; Hallek M; Frenzel LP; Krause G
Int J Cancer; 2015 Nov; 137(9):2234-42. PubMed ID: 25912635
[TBL] [Abstract][Full Text] [Related]
28. IPI-145 shows promise in CLL patients.
Cancer Discov; 2014 Feb; 4(2):136. PubMed ID: 24501284
[TBL] [Abstract][Full Text] [Related]
29. Rituximab for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Hagemeister F
Drugs; 2010 Feb; 70(3):261-72. PubMed ID: 20166765
[TBL] [Abstract][Full Text] [Related]
30. Idelalisib for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma.
Barrientos JC
Future Oncol; 2016 Sep; 12(18):2077-94. PubMed ID: 27324214
[TBL] [Abstract][Full Text] [Related]
31. [Ibrutinib prescription in B-cell lymphoid neoplasms].
Dougé A; Ravinet A; Bay JO; Tournilhac O; Guièze R; Lemal R
Bull Cancer; 2016 Feb; 103(2):127-37. PubMed ID: 26822906
[TBL] [Abstract][Full Text] [Related]
32. A phase 1b/2 study of duvelisib in combination with FCR (DFCR) for frontline therapy for younger CLL patients.
Davids MS; Fisher DC; Tyekucheva S; McDonough M; Hanna J; Lee B; Francoeur K; Montegaard J; Odejide O; Armand P; Arnason J; Brown JR
Leukemia; 2021 Apr; 35(4):1064-1072. PubMed ID: 32820271
[TBL] [Abstract][Full Text] [Related]
33. Phase I study of duvelisib in Japanese patients with relapsed or refractory lymphoma.
Izutsu K; Kato K; Kiyoi H; Yamamoto G; Shimada K; Akashi K
Int J Hematol; 2020 Oct; 112(4):504-509. PubMed ID: 32613313
[TBL] [Abstract][Full Text] [Related]
34. Idelalisib: a review of its use in chronic lymphocytic leukaemia and indolent non-Hodgkin's lymphoma.
Keating GM
Target Oncol; 2015 Mar; 10(1):141-51. PubMed ID: 25637459
[TBL] [Abstract][Full Text] [Related]
35. Duvelisib, an oral dual PI3K-δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study.
O'Brien S; Patel M; Kahl BS; Horwitz SM; Foss FM; Porcu P; Jones J; Burger J; Jain N; Allen K; Faia K; Douglas M; Stern HM; Sweeney J; Kelly P; Kelly V; Flinn I
Am J Hematol; 2018 Nov; 93(11):1318-1326. PubMed ID: 30094870
[TBL] [Abstract][Full Text] [Related]
36. Novel agents in the treatment of chronic lymphocytic leukemia: a review about the future.
Desai AV; El-Bakkar H; Abdul-Hay M
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):314-22. PubMed ID: 25445466
[TBL] [Abstract][Full Text] [Related]
37. Ibrutinib, idelalisib and obinutuzumab for the treatment of patients with chronic lymphocytic leukemia: three new arrows aiming at the target.
Morabito F; Gentile M; Seymour JF; Polliack A
Leuk Lymphoma; 2015; 56(12):3250-6. PubMed ID: 26062943
[TBL] [Abstract][Full Text] [Related]
38. Umbralisib: First Approval.
Dhillon S; Keam SJ
Drugs; 2021 May; 81(7):857-866. PubMed ID: 33797740
[TBL] [Abstract][Full Text] [Related]
39. Therapy of chronic lymphocytic leukemia with purine analogs and monoclonal antibodies.
Robak T
Transfus Apher Sci; 2005 Feb; 32(1):33-44. PubMed ID: 15737872
[TBL] [Abstract][Full Text] [Related]
40. [Zanubrutinib - Relapsed or refractory follicular lymphoma].
Grant-Monlouis-Felicite F; Diop N
Bull Cancer; 2024 Jun; 111(6):542-544. PubMed ID: 38582740
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]